Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Daiichi Sankyo acquires members of Merck Serono’s Turkish cardio-metabolism sales team

Daiichi Sankyo acquires members of Merck Serono’s Turkish cardio-metabolism sales team

4th November 2008

Daiichi Sankyo Ilac Ticaret, Daiichi Sankyo’s Turkish subsidiary, has acquired 20 members of Merck Serono’s sales force in the country.

The agreement with Merck Ilac – the company’s subsidiary in Turkey – includes the marketing authorisation transfer of anti-hypertensive drug Concor and diabetes agent Glucophage, according to reports.

Ilker Ozbay, managing director of Daiichi Sankyo Ilac Ticaret, said obtaining new staff and medication rights has enabled the company to approach "the critical mass needed to reach our company goals and to become one of the leading 15 pharmaceutical companies in Turkey by 2015".

Daiichi Sankyo’s sales team will also need to be strengthened to prepare the company for the introduction of products to Turkey in coming years, he added.

The launch of three new anti-hypertensive and anti-platelet products is planned for Turkey and throughout Europe between 2009 and 2012.

People in scientific sales jobs may be interested in Daiichi Sankyo’s affiliates in 11 European countries.

ADNFCR-1050-ID-18857215-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.